keyword
MENU ▼
Read by QxMD icon Read
search

Meningococcal Serogroup B Vaccine

keyword
https://www.readbyqxmd.com/read/28992986/pros-and-cons-of-vaccination-against-disease-caused-by-serogroup-b-meningococcal-disease
#1
REVIEW
Miguel Delgado Rodríguez, Ángela Domínguez García
A vaccine has recently been approved in the EU against meningococcal serogroup B, the main cause of meningococcal disease. There is a fierce debate about the decision regarding a universal vaccination in infants older than 2 months, as recommended by the majority of scientific societies. In western Europe the only country to have included the universal vaccination is the United Kingdom, with a lower incidence of the disease than Ireland. Other countries have also adopted it, such as the Czech Republic, Cuba and certain regions of Italy...
October 7, 2017: Medicina Clínica
https://www.readbyqxmd.com/read/28968661/meningococcal-carriage-following-a-university-serogroup-b-meningococcal-disease-outbreak-and-vaccination-campaign-with-menb-4c-and-menb-fhbp-oregon-2015-2016
#2
Lucy A McNamara, Jennifer Dolan Thomas, Jessica MacNeil, How Yi Chang, Michael Day, Emily Fisher, Stacey Martin, Tasha Poissant, Susanna E Schmink, Evelene Steward-Clark, Laurel Thompson Jenkins, Xin Wang, Anna Acosta
Background: Limited data exist on the impact of the serogroup B meningococcal (MenB) vaccines MenB-FHbp and MenB-4C on meningococcal carriage and herd protection. We therefore assessed meningococcal carriage following a MenB vaccination campaign in response to a university serogroup B meningococcal disease outbreak in 2015. Methods: A convenience sample of students recommended for vaccination provided oropharyngeal swabs and completed questionnaires during four carriage surveys over 11 months...
August 26, 2017: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/28903515/update-from-the-advisory-committee-on-immunization-practices
#3
Sean T O'Leary, Yvonne A Maldonado, Carrie L Byington
The Advisory Committee on Immunization Practices (ACIP), a group of medical and public health experts, meets 3 times per year to develop recommendations for vaccine use in the United States. The group has 15 voting members, and each member's term is 4 years. ACIP members and Centers for Disease Control and Prevention (CDC) staff discuss the epidemiology of vaccine-preventable diseases and vaccine research, effectiveness, safety data, and clinical trial results. Representatives from the American Academy of Pediatrics (C...
September 1, 2017: Journal of the Pediatric Infectious Diseases Society
https://www.readbyqxmd.com/read/28794055/effect-of-vaccine-elicited-antibodies-on-colonization-of-neisseria-meningitidis-serogroup-b-and-c-strains-in-a-human-bronchial-epithelial-cell-culture-model
#4
Vianca Vianzon, Beate Illek, Gregory R Moe
Capsular polysaccharide-protein conjugate vaccines protect individuals from invasive disease and decrease carriage, which reduces spread of the organism in the population. In contrast, antibodies elicited by plain polysaccharide or protein antigen-based meningococcal (Men) vaccines have little or no effect on decreasing carriage. In this study, we investigated the mechanism by which vaccine-induced human IgG antibodies affect colonization by serogroup B (MenB) or C (MenC) strains using a human bronchial epithelial cell culture model (16HBE14o-)...
August 9, 2017: Clinical and Vaccine Immunology: CVI
https://www.readbyqxmd.com/read/28770496/serogroup-b-meningococcus-outbreaks-prevalence-and-the-case-for-standard-vaccination
#5
REVIEW
James Grogan, Karen Roos
PURPOSE OF REVIEW: This review explores the history of serogroup B meningitis outbreaks in American universities and the rise of the monovalent serogroup B meningococcus vaccines (MenB). RECENT FINDINGS: Serogroup B meningitis represents 30% of American meningococcal infections and had no commercially available vaccine in the USA until 2013 when the FDA made an expanded allowance for importation of the MenB-4C vaccine for outbreaks at two American universities. Infections of Neisseria meningitidis, notably meningococcal meningitis represent a continued, lethal threat to the pediatric and adolescent populations and those with primary or acquired complement component deficiencies, largely mitigated by the quadrivalent meningococcal conjugated vaccine against serogroups A, C, W, and Y (MenACWY)...
September 2017: Current Infectious Disease Reports
https://www.readbyqxmd.com/read/28739825/neisseria-cinerea-expresses-a-functional-factor-h-binding-protein-which-is-recognised-by-immune-responses-elicited-by-meningococcal-vaccines
#6
Hayley Lavender, Katy Poncin, Christoph M Tang
Neisseria meningitidis is a major cause of bacterial meningitis and sepsis worldwide. Capsular polysaccharide vaccines are available against meningococcal serogroups A, C, W and Y. More recently two protein based vaccines, Bexsero® and Trumenba®, have been licenced against meningococcal serogroup B strains; both vaccines contain meningococcal factor H binding protein (fHbp). fHbp is a surface exposed lipoprotein which binds the negative complement regulator, complement factor H (CFH), thereby inhibiting the alternative pathway of complement activation...
July 24, 2017: Infection and Immunity
https://www.readbyqxmd.com/read/28729920/annual-vaccine-preventable-disease-report-for-new-south-wales-australia-2014
#7
Nathan Saul, Robin Gilmour, Paula Spokes
This report provides an epidemiological description of selected vaccine-preventable diseases in New South Wales (NSW), Australia, for 2014 to inform ongoing disease monitoring and control efforts. A trend of increasing pertussis notifications was observed, beginning midway through 2014 with the highest disease rates in the 5-9 year age group. Measles notifications increased to 67 cases in 2014 from 34 cases in 2013. Measles cases were associated with travel-related importations-predominantly from the Philippines-and secondary transmission increased compared to 2013 involving three main disease clusters...
April 2017: Western Pacific Surveillance and Response Journal: WPSAR
https://www.readbyqxmd.com/read/28668575/meningococcal-serogroup-c-immunogenicity-antibody-persistence-and-memory-b-cells-induced-by-the-monovalent-meningococcal-serogroup-c-versus-quadrivalent-meningococcal-serogroup-acwy-conjugate-booster-vaccine-a-randomized-controlled-trial
#8
Mariëtte B van Ravenhorst, Fiona R M van der Klis, Debbie M van Rooijen, Mirjam J Knol, Susanne P Stoof, Elisabeth A M Sanders, Guy A M Berbers
BACKGROUND: Adolescents are considered the key transmitters of meningococci in the population. Meningococcal serogroup C (MenC) antibody levels wane rapidly after MenC conjugate vaccination in young children, leaving adolescents with low antibody levels. In this study, we compared MenC immune responses after booster vaccination in adolescence with either tetanus toxoid conjugated MenC (MenC-TT) or MenACWY (MenACWY-TT) vaccine, and aimed to establish an optimal age for this booster. METHODS: Healthy 10-, 12-, and 15-year-olds, who received a single dose of MenC-TT vaccine in early childhood, were randomized to receive MenC-TT or MenACWY-TT vaccine...
June 28, 2017: Vaccine
https://www.readbyqxmd.com/read/28651843/-neisseria%C3%A2-meningitidis-urethritis-two-case-reports
#9
C Dubois, A-L Liegeon, C Fabbro, F Truchetet
BACKGROUND: Neisseria meningitidis (NM) is a commensal bacteria present in the oropharyngeal flora that causes invasive infections. There have been rarer reports of presence in the genital region. Herein, we present two cases of acute NM urethritis. PATIENTS AND METHODS: Two men aged 30 and 31years, one of whom is homosexual and seropositive for HIV infection, presented urethral discharge which was diagnosed as acute urethritis. The unit through samples indicated the presence of NM of serogroups B and C...
October 2017: Annales de Dermatologie et de Vénéréologie
https://www.readbyqxmd.com/read/28651840/the-role-of-anti-nhba-antibody-in-bactericidal-activity-elicited-by-the-meningococcal-serogroup-b-vaccine-menb-4c
#10
Elizabeth Partridge, Eduardo Lujan, Serena Giuntini, David M Vu, Dan M Granoff
BACKGROUND: MenB-4C (Bexsero®) is a multicomponent serogroup B meningococcal vaccine. For vaccine licensure, efficacy was inferred from serum bactericidal antibody (SBA) against three antigen-specific indicator strains. The bactericidal role of antibody to the fourth vaccine antigen, Neisserial Heparin binding antigen (NHba), is incompletely understood. METHODS: We identified nine adults immunized with two or three doses of MenB-4C who had sufficient volumes of sera and >3-fold increases in SBA titer against a strain with high NHba expression, which was mismatched with the other three MenB-4C antigens that elicit SBA...
July 24, 2017: Vaccine
https://www.readbyqxmd.com/read/28647167/adolescent-meningococcal-serogroup-a-w-and-y-immune-responses-following-immunization-with-quadrivalent-meningococcal-a-c-w-and-y-conjugate-vaccine-optimal-age-for-vaccination
#11
Mariëtte B van Ravenhorst, Fiona R M van der Klis, Debbie M van Rooijen, Elisabeth A M Sanders, Guy A M Berbers
BACKGROUND: Recently the incidence of meningococcal serogroup Y (MenY) and in particular serogroup W (MenW) invasive disease has risen in several European countries, including the Netherlands. Adolescents are a target group for primary prevention through vaccination to protect against disease and reduce carriage and induce herd protection in the population. The present study assessed MenA, MenW and MenY antibody levels in adolescents up to one year following primary vaccination with quadrivalent MenACWY-PS conjugated to tetanus toxoid (MenACWY-TT)...
June 21, 2017: Vaccine
https://www.readbyqxmd.com/read/28630122/eculizumab-treatment-and-impaired-opsonophagocytic-killing-of-meningococci-by-whole-blood-from-immunized-adults
#12
Monica Konar, Dan M Granoff
Eculizumab, a humanized anti-complement C5 monoclonal antibody (mAb) for treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome, blocks the terminal complement pathway required for serum bactericidal activity (SBA). Because treated patients are at >1000-fold increased risk of meningococcal disease, vaccination is recommended; whether vaccination can protect by opsonophagocytic activity in the absence of SBA is not known. Meningococci were added to anticoagulated blood from 12 healthy adults vaccinated with meningococcal serogroup B and serogroup A, C, W, Y vaccines...
August 17, 2017: Blood
https://www.readbyqxmd.com/read/28599793/a-cross-reacting-material-crm197-conjugate-vaccine-induces-diphtheria-toxin-neutralizing-antibody-response-in-children-and-adolescents-infected-or-not-with-hiv
#13
Giselle P Silva, Rafaela S Santos, Wânia F Pereira-Manfro, Bianca Ferreira, Daniella M Barreto, Ana Cristina C Frota, Cristina B Hofer, Lucimar G Milagres
Anti-diphtheria antibody levels decrease with aging, and frequent booster vaccinations are required to maintain herd immunity. We analyzed the diphtheria toxin neutralizing antibody (DT-Nab) response induced by a conjugate vaccine (meningococcal C polysaccharide-CRM197) in HIV-vertically infected (HI) children and adolescents and healthy controls (HC) with matched age. We report the association of DT-Nab with the bactericidal antibodies to serogroup C meningococcus (MenC). Before vaccination, 21 HI patients (50%) had no protection against diphtheria (≤0...
June 6, 2017: Vaccine
https://www.readbyqxmd.com/read/28583305/immunogenicity-and-safety-of-a-new-hexavalent-vaccine-dtap5-ipv-hb-hib-administered-in-a-mixed-primary-series-schedule-with-a-pentavalent-vaccine-dtap5-ipv-hib
#14
Federico Martinón-Torres, Florence Boisnard, Stéphane Thomas, Christine Sadorge, Ray Borrow
DTaP5-IPV-HB-Hib vaccine is a fully-liquid, combination hexavalent vaccine. This phase III, open-label, multicentre study conducted in Spain, evaluated the immune response to all DTaP5-IPV-HB-Hib antigens when the vaccine was used in a mixed hexa/penta/hexa primary series. Infants (who had received one dose of hepatitis B vaccine at birth) received a mixed schedule including DTaP5-IPV-HB-Hib (PRP-OMP conjugate) at 2 and 6months of age, DTaP5-IPV-Hib at 4months, meningococcal serogroup C conjugate (MCC) vaccine at 2 and 4months, and routine rotavirus and pneumococcal vaccination...
June 2, 2017: Vaccine
https://www.readbyqxmd.com/read/28582542/serum-bactericidal-antibody-responses-of-students-immunized-with-a-meningococcal-serogroup-b-vaccine-in-response-to-an-outbreak-on-a-university-campus
#15
Eduardo Lujan, Kathleen Winter, Jillandra Rovaris, Qin Liu, Dan M Granoff
Background.: MenB-4C is a recently licensed meningococcal serogroup B vaccine. For vaccine licensure, short-term efficacy was inferred from serum bactericidal antibody (SBA) titers against three antigen-specific indicator strains, which are not necessarily representative of U.S. disease-causing strains. Methods.: 4923 students were immunized with MenB-4C in response to an outbreak at a university. Serum samples were obtained at 1.5 to 2 months from 106 students who received the recommended 2 doses and 52 unvaccinated students...
June 3, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/28581267/characterization-of-oropharyngeal-carriage-isolates-of-neisseria-meningitidis-in-healthy-korean-adolescents-in-2015
#16
Han Wool Kim, Soyoung Lee, Daeho Kwon, Jihei Cha, Jong Gyun Ahn, Kyung Hyo Kim
The meningococcus carriage rate is age-dependent, with a high prevalence in adolescents and young adults. This cross-sectional study aimed to estimate the oropharyngeal carriage rate of meningococcus among healthy Korean adolescents and its relationship with several population characteristics. The survey was conducted from April to May 2015 among 1,460 first-year high-school students in 9 high schools located in Gyeonggi province, Korea. Each student answered a short questionnaire assessing risk factors for carriage, and posterior pharyngeal wall swab samples were obtained...
July 2017: Journal of Korean Medical Science
https://www.readbyqxmd.com/read/28579305/frequent-capsule-switching-in-ultra-virulent-meningococci-are-we%C3%A2-ready-for-a-serogroup-b-st-11-complex%C3%A2-outbreak
#17
Jay Lucidarme, Aiswarya Lekshmi, Sydel R Parikh, James E Bray, Dorothea M Hill, Holly B Bratcher, Steve J Gray, Anthony D Carr, Keith A Jolley, Jamie Findlow, Helen Campbell, Shamez N Ladhani, Mary E Ramsay, Martin C J Maiden, Ray Borrow
The meningococcal ST-11 complex (cc11) causes large invasive disease outbreaks with high case fatality rates, such as serogroup C (MenC) epidemics in industrialised nations in the 1990s and the serogroup W epidemic currently expanding globally. Glycoconjugate vaccines are available for serogroups A, C, W and Y. Broad coverage protein-based vaccines have recently been licensed against serogroup B meningococci (MenB), however, these do not afford universal MenB protection. Capsular switching from MenC to MenB among cc11 organisms is concerning because a large MenB cc11 (B:cc11) outbreak has the potential to cause significant morbidity and mortality...
August 2017: Journal of Infection
https://www.readbyqxmd.com/read/28566335/breadth-and-duration-of-meningococcal-serum-bactericidal-activity-in-health-care-workers-and-microbiologists-immunized-with-the-menb-fhbp-vaccine
#18
Eduardo Lujan, Elizabeth Partridge, Serena Giuntini, Sanjay Ram, Dan M Granoff
MenB-FHbp is a meningococcal serogroup B vaccine with two factor H binding protein (FHbp) antigens from subfamilies A and B. For licensure, efficacy was inferred from serum bactericidal antibody (SBA) responses to four reference strains. Only limited information is available on the breadth or duration of protective SBA responses to genetically diverse disease-causing strains. Seventeen health care or laboratory workers were immunized with two (n = 2) or three (n = 15) doses of MenB-FHbp at 0, 2, and 6 months...
August 2017: Clinical and Vaccine Immunology: CVI
https://www.readbyqxmd.com/read/28557743/understanding-the-category-b-recommendation-for-serogroup-b-meningococcal-vaccine
#19
Gary S Marshall, Litjen Tan
No abstract text is available yet for this article.
May 2017: Pediatrics
https://www.readbyqxmd.com/read/28533054/reduced-schedules-of-4cmenb-vaccine-in-infants-and-catch-up-series-in-children-immunogenicity-and-safety-results-from-a-randomised-open-label-phase-3b-trial
#20
Federico Martinón-Torres, Marco Aurelio P Safadi, Alfonso Carmona Martinez, Pilar Infante Marquez, Juan Carlos Tejedor Torres, Lily Yin Weckx, Edson Duarte Moreira, Ilhem Mensi, Marco Calabresi, Daniela Toneatto
BACKGROUND: This study evaluated the immunogenicity and safety of a licensed meningococcal serogroup B vaccine (4CMenB) administered alone according to reduced schedules in infants or catch-up series in children. METHODS: In this open-label, multicentre, phase 3b study (NCT01339923), infants randomised 1:1:1 received 4CMenB: 2+1 doses at 3½-5-11months or 6-8-11months of age, 3+1 doses at ages 2½-3½-5-11months. Children aged 2-10years received 2 catch-up doses administered 2months apart...
June 16, 2017: Vaccine
keyword
keyword
49014
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"